Abnormal activation of c-Met in lung cancer and research progress of the targeted drugs: A review
10.3724/SP.J.1008.2013.00557
- Author:
Xu CAO
1
Author Information
1. Department of Pathology, Shanghai Pulmonary Hospital, Tongii University School of Medicine
- Publication Type:Journal Article
- Keywords:
Lung neoplasms;
Proto-oncogene proteins c-Met;
Targeted therapy
- From:
Academic Journal of Second Military Medical University
2013;34(5):557-560
- CountryChina
- Language:Chinese
-
Abstract:
c-Met is a receptor tyrosine kinase (RTK) with hepatocyte growth factor (HGF) as its natural ligand. c-Met may be activated in a ligand-dependent manner by binding HGF or in a ligand-independent manner. Diverse activation mechanisms of c-Met exist in many malignant tumors, including lung cancer. Moreover, the abnormal activation of c-Met has a close relationship with the occurrence, development and malignant biological behavior of lung cancer. This paper focused on the different activation mechanisms of c-Met in non-small cell lung cancer and small cell lung cancer and also reviewed the research progress of c-Met targeted drugs in lung cancer.
